Genetic variation in the androgen metabolizing enzymes is important to identify and feature as they may influence the risk of prostate cancer and help clarify the etiology of the disease. Human 17b-hydroxysteroid dehydrogenase type 5 (AKR1C3) is highly expressed in the prostate gland and plays a major role in the formation and metabolism of androgens. We identified five novel polymorphisms in the AKR1C3 gene. One of those an A4G substitution in exon 2 that confers a Glu77Gly change occurred in 4.8% in Caucasians but was completely absent in Orientals. Interestingly, the testosterone level in serum was significantly lower in subjects with the Gly77 allele. A promoter A4G polymorphism was associated with significantly altered promoter activity in reporter constructs, but was not associated with any change in testosterone levels. In conclusion, the Glu77Gly polymorphism is associated with lower testosterone levels in serum.
Introduction
Testosterone and dihydrotestosterone (DHT) are the most potent male androgens. Although testosterone is one of the major androgens in the circulation, DHT is a key androgen in peripheral tissues, particularly in the prostate. 1 The action of these androgens is mediated via the androgen receptor (AR) and is crucial for men's health. 2 Testosterone and DHT are strongly associated with the development and progress of prostate cancer. 3 Therefore, it is of great interest to identify and feature genetic variation in the pathways of the metabolic network of androgens.
Human 17b-hydroxysteroid dehydrogenase (17b-HSD) type 5 is identical to human type 2 3a-hydroxysteroid dehydrogenase (3a-HSD) 4 and belongs to the aldoketo reductase (AKR) superfamily. 5 It is formally known as AKR1C3. It is a promiscuous enzyme that participates in the biosynthesis and metabolism of a variety of substrates including androgens, estrogens, 4 prostaglandins 6 and polycyclic aromatic hydrocarbons (PAH). 7 AKR1C3 is widely expressed in human tissues and is predominant in the prostate and mammary gland.
The 17-keto reductase activity of AKR1C3 reduces the weak androgen D 4 -androstenedione (4-dione) to testosterone. It also reduces estrone to 17b-estradiol, which has high affinity for the estrogen receptor (ER). The combined 3a/3b activity of the enzyme 8 partly inactivates 5a-DHT to the weak androgens 3a-androstanediol (3a-Adiol) and 3b-androstanediol (3b-Adiol) and the 17b-hydroxysteroid oxidase activity of the enzyme oxidizes 3a-Adiol to androsterone instead of back to DHT. 4 The AKR1C3 gene consists of nine exons and is located on chromosome 10p15-p14 together with the other AKR1C members. 9 Several putative single nucleotide polymorphisms (SNPs) in this gene have been reported to the Entrez SNP Data Base (http://www.ncbi.nlm.nih.gov/SNP/) but none of them has been cloned and characterized. One of the SNPs, a non-synonymous c.15G4C [p.Q5H] in exon 1 (Table 1) , has recently been associated with an increased risk of lung cancer 10 and the silent c.90G4A has been associated with a decreased prostate volume. 11 Recently an A4G polymorphism in the promoter region (g.2960A4G) (AB032154) at nucleotide position À138 from the translation start site was identified 12 and characterized. 13 The allele frequency of this SNP was shown to be significantly increased in patients with polycystic ovary syndrome (PCOS). 13 Here, we used the human expressed sequence tag (EST) database to search for polymorphisms in the AKR1C3 gene together with single-strand conformation polymorphism (SSCP) analysis. Five SNP were detected, one of which was likely to alter the expression pattern and enzyme activity. The activity of this polymorphism and the A4G promoter SNP 13 were investigated in reporter and expression systems. We also investigated the allele frequencies in a group of individuals of Caucasian and Asian ethnicity. Testosterone levels were determined in serum of the study subjects for comparison with the genotypes.
Results
Identification of several polymorphisms in the AKR1C3 gene Six possible polymorphisms were detected using the in silico search. Only two of these, the 3 0 -end non-coding polymorphisms (c.972 þ 7A4G and c.972 þ 8A4G), were confirmed by SSCP/direct sequence analysis as indicated in Table 1 . Four additional polymorphisms were detected by SSCP/direct sequence analysis (Table 1) . A recently reported 12 and characterized 13 A4G substitution in the promoter region (g.2960A4G) (AB032154) at nucleotide position À138 from the translation start site that alter the affinity for upstream stimulating factor (USF) according to a computer analysis 14 was identified in 12 of 40 individuals. An A4G substitution in exon 2, that alters the amino acid glutamic acid to glycine was found (c.230A4G [p.E77G]). Moreover, a nucleotide substitution in intron 8 (c.929 þ 40A4G) and a silent mutation in exon 2 (c.90G4A [p.P30P]) were identified. The promoter polymorphism and the non-synonomous polymorphism in exon 2 are more likely to alter the expression and/or the enzyme activity than the other and were therefore investigated further regarding allele frequency and phenotypic consequences.
Allele frequency
The frequencies of two AKR1C3 polymorphisms were determined in two ethnic populations, including 1045 Swedish and 157 Korean individuals. The frequency of the uncommon allele in the exon 2 (p.Glu77Gly) polymorphism was 4.8% in the Swedish population (n ¼ 1045) but 0% in the Korean population (n ¼ 157). The frequency of the G-allele of the promoter variant was 0.65% in Koreans (n ¼ 153) and 34.4% in Swedes (n ¼ 762). The results are summarized in Tables 2a and 2b . 
Serum testosterone and genotype
The Swedish subjects with the Gly77 variant of AKR1C3 had significantly lower levels of total serum testosterone (P ¼ 0.034) and free serum testosterone (P ¼ 0.015) than the subjects with the Glu77 AKR1C3 enzyme. The results are summarized in Table 3 . The promoter polymorphism had no significant effects on testosterone levels in serum ( Table 3) . As there were only two Korean subjects being heterozygotes for the promoter polymorphism and no one having the exon 2 polymorphism, serum was not analyzed for testosterone in this group.
Functional analysis of the human AKR1C3 promoter polymorphism The promoter activity was investigated in A549, human hepatoma cells (HepG2) and LNCaP cells. The normalized luciferase activities of the G-construct was 34715% (P ¼ 0.039), 51721% (P ¼ 0.012) and 53721% (P ¼ 0.045) lower than the A-constructs in A549 cells, HepG2 cells and LNCaP cells, respectively.
Western blotting
In order to confirm the expression of the two variants of the AKR1C3 protein the bacterial cytosols were subjected to Western blotting of the Glu77 and Gly77 variants of the enzyme. Both 36.7 kDa proteins were recognized by the dihydrodiol dehydrogenase antibody (not shown).
Functional analysis of human AKR1C3 exon 2 polymorphism
The wild-type and the polymorphic variants of the enzyme were cloned and expressed in bacteria. The enzyme activities with different substrates are summarized in Table 4 . There was a tendency of lower activity of the polymorphic Gly77 enzyme in the formation of testosterone from androstenedione. The difference was however not significant (P ¼ 0.092).
Discussion
We here report a novel polymorphism in one of the key enzyme genes in androgen metabolism, AKR1C3. The SNP (Glu77Gly) in exon 2 was associated with lower testosterone levels. When comparing serum (n ¼ 1022) levels of testosterone the heterozygotes (Glu77/Gly77) showed significantly lower levels than the homozygotes (Glu77/Glu77) ( Table 3) . We did not find any homozygotes for the Gly77 allele in our material albeit 2-3 such individuals were expected.
Even though this enzyme is multi-specific and displays both 3-, 17-and 20-ketosteroid reductase and 3a-, 17b and 20a-hydroxysteroid oxidase activity in vitro 15 the preferred catalytic reaction is the17b-reduction. 16 17b Hydroxosteroid dehydrogenase type 3 synthesizes testosterone from D 4 -androstenedione (4-dione) in the Leydig cells of the testes generating approximately 50% of the total amount of androgens in men. 17 The remaining amount of testosterone is produced by AKR1C3 in target tissues such as the prostate. About 50% of androgens in the prostate are locally Table 3 Serum levels of testosterone (T) in Swedish Caucasian males with different genotypes shown as the mean with the 95% CI within parenthesis Lower serum testosterone levels in caucasian men
synthesized from the inactive adrenal precursors dehydroepiandrosterone (DHEA) and DHEA-sulfate. 17 Considering that the 230A4G SNP is associated with lower testosterone levels in serum it is possible that this polymorphism may have a greater effect on intracellular testosterone levels in peripheral tissues than is reflected in the serum. If this is true then the AKR1C3 polymorphism may influence the risk of certain androgen-dependent diseases, but this remains to be shown. The frequency of the promoter A allele was 99.3% in Koreans and only 65.6% in Swedes. As a corollary, there was a 52-fold difference in the frequency of the G allelic variant between these populations. This is interesting in view of the large difference in prostate cancer incidence between these ethnic groups, 18 with a more than 10 times higher incidence among Swedish than Korean men; 115 per 100 000 in 1992, 1 compared to 10.1 per 100 000 in South Koreans 1985-1999. 19 DHT, one of the substrates of the AKR1C3 enzyme and the corresponding 3b-Adiol product are ligands of the AR and ER b , respectively. 20 It may be speculated that genetic variants of AKR1C3 that are associated with an increased activity may shift the balance between the receptor actions Lower serum testosterone levels in caucasian men J Jakobsson et al in favor of the ERb. Such a shift might counteract the proproliferative results of AR activation. 21 On the other hand, increased activity of the enzyme may be disadvantageous, as AKR1C3 also converts androstenedione to testosterone, which is subsequently converted to DHT in the prostate. 22 Our in vitro studies showed no significant change in enzyme activity between the two variants expressed in bacteria. The crude cell lysates used in this study may not be sensitive enough to detect a possible 10% decrease in activity. Differences in in vitro and in vivo results may also result from post-translational events. Hence bacteria may not be an ideal system for investigating this enzyme. The enzymes were not purified by us from the bacterial cytosols. However Steckelbroeck et al. 8 have shown that cytosol from transformed Escherichia coli gave the same product profiles as the respective homogeneous recombinant AKR1C3 enzyme. The K m and V max values obtained from the transformed bacterial host cells are, however, not comparable with those of purified enzyme.
In vitro, the promoter G allelic variant displayed a 30-50% lower activity than the A variant in human prostate, lung and liver cells, where the AKR1C3 gene is highly expressed. 4 We did, however, not find any significant association between this polymorphism and the testosterone levels in serum in our male Caucasian subjects, although there was a tendency towards lower levels in the G/G group in agreement with the in vitro results (Table 3 ). In contrast Qin et al. 13 found a 70% higher activity of the G allelic promoter in rat theca cells and an association between the G/G allele and PCOS. There were also quite large differences in allele frequencies between our Swedish Caucasians and their Caucasian control group. We have no explanation for this inconsistency, but differences in cell lines (rat theca cells vs. human prostate, lung and liver cells), length of promoter fragment cloned into the luciferase vector as well as number of subjects genotyped may play a role.
AKR1C3 is also known as a dihydrodiol dehydrogenase and oxidizes PAH trans-dihydrodiols to reactive and redox active o-quinones which are highly genotoxic. 7 High expression of AKR1C isoforms in non-small cell lung carcinoma was shown to be a prognostic marker of poor disease outcome. 23 Recently Lan et al. 10 found an association between a c.15G4C [p.Q5H] polymorphism with an increased risk of PAH-induced lung cancer in a Chinese population. This SNP was also identified by us in silico (Table  1 ) but could not be confirmed by polymerase chain reaction (PCR)-direct sequence analyses of 20 alleles from Korean and Swedish subjects. The SNP has not been functionally evaluated. The allelic G variant in the promoter described in this work showed a significantly lower transcriptional activity than the A variant in human lung cancer cell line A549. Therefore one might speculate that the promoter polymorphism could be associated with lower morbidity in PAH-induced lung cancer. The Glu77Gly enzyme activity towards PAH-trans dihydrodiols has not been evaluated here.
The other SNPs located in exon 2 (c.90G4A [p.P30P]), intron 8 (c.929 þ 40A4G) and intron 9 (c.972 þ 7A4G and c.972 þ 8A4G) were not investigated in respect of enzyme activity and allele frequency in this work. It is possible that the intron SNPs affect the splicing of the enzyme, the stability of the transcript and/or are linked to each other and affect enzyme activity in vivo.
In conclusion, we have characterized one novel polymorphism in the AKR1C3 gene. The non-conservative p.Glu77Gly polymorphism in exon 2 was associated with significantly lower concentrations of total and free testosterone in serum.
We have also investigated the recently reported A4G polymorphism located in the promoter, 12, 13 which showed a significantly lower activity in two different expression systems, human prostate, liver and lung cells. Whether this polymorphism is associated with any clinically important pathophysiology in males remains to be studied.
Materials and methods

Chemicals
All steroids used were obtained from Sigma-Aldrich (St Louis, MO, USA) except for DHT, which was obtained from Steraloids.
Study population and sample selection
We investigated the allele frequency in two populations of Caucasian and Asian ethnicity. Korean individuals (n ¼ 157) were randomly selected from two previous studies. 24, 25 The population consisted of healthy unrelated men and women from different areas in Korea. The Ethics Committee of Karolinska Institutet at Karolinska University Hospital approved this part of the study.
The Caucasian sample population was selected from The Gothenburg Osteoporosis and Obesity Determinants (GOOD) study, which was initiated with the aim to determine both environmental and genetic factors for bone and fat mass. The study was approved by the Ethics committee at the Gothenburg University and written informed consent was obtained from all study subjects. The GOOD cohort consists of 1068 men, aged 18.0-20.1 years (mean 18.970.6 years), from the greater Gothenburg area. Study subjects were randomly identified using national population registers, contacted by telephone and asked to participate in the present study. Only Caucasians (n ¼ 1045) were selected for genotyping in this study excluding a minor group of Hispanics and Asians.
Serum testosterone and SHBG assays
Whole blood was obtained from the subjects and collected in etylenediaminetetraacetic acid tubes for DNA extraction. In the Swedish population blood was also collected in gel containing tubes from which serum was extracted using standardized procedures, immediately frozen and stored at À801C until analysis. To minimize any influence of diurnal variation all blood samples were collected between 15 taking the concentrations of total testosterone and SHBG into account, and assuming a fixed albumin concentration of 43 g/l. Detection limits were for testosterone 0.1 nmol/l and for SHBG 1.3 nmol/l. Cross-reactivity towards other androgens were; DHT 4.5% androstandione 0.03%. 5-androstendiol 0.02% and for other steroids the specificity was less than 0.02%. The intra-and inter-assay precision of the testosterone assay in the range of 10-20 nM was 3.8 and 4.8%, respectively. Within and between assay coefficients of variation were for testosterone 5.5 and 5.8% and for SHBG 2.5 and 6.9%, respectively.
Sequence numbering
Sequence numbering follows the recommendations indicated in the website www.hgvs.org/mutnomen. AKR1C3 nucleotides are numbered throughout the study considering the A of the first ATG as nucleotide þ 1 as recommended.
In silico analysis
Potential polymorphisms in the AKR1C3 gene (ref sequences AB032154, AB032155, AB032156 and AB032157) were identified using the EST database and a basic local alignment search tool alignment tool as described previously. [28] [29] [30] When the indicated mutation gave rise to a non-conservative amino acid change a PCR-direct sequence analysis of 10 subjects was performed to verify the potential polymorphisms.
SSCP-PCR sequencing
SNPs in the AKR1C3 gene were searched for and identified by PCR-SSCP analysis in a Swedish and a Korean population sample as described previously 31 using the intron specific SSCP primers listed in Table 5a . The PCR products were purified using PCR purification kit (Qiagen, Hilden, Germany) and sequence analyzed using Big Dye Terminator Kit v2 (Applied Biosystem, Foster City, CA, USA) and an ABI Prism 377 DNA sequencer.
PCR-assay
To genotype the A4G polymorphism in the promoter and the A4G polymorphism in exon 2, fluorogenic 5 0 nuclease PCR (TaqMan) according to the principle reviewed by Livak 32 was employed as described. 31 The primers and probes are listed in Table 5b . The exon 2-SNP analysis required amplification through 14 PCR cycles with different sets of primers (Table 5b ) yielding a 463 bp product involving denaturation at 941C, annealing at 551C for 45 s and extension at 721C for 45 s. The PCR product was then used as template in the Taqman procedure. This extra step was necessary to avoid the amplification of other AKR1C genes that are highly homologous to AKR1C3.
The data from the ABI Prism 7700 Sequence Detector were plotted in a graph in which the outcome and quality of the allelic discrimination, was assessed. Non-template controls were used for detection of DNA contamination, but no such contamination was detected during the investigation.
Cell culture
Human alveolar cells (A549), were cultured in Dulbecco's modified Eagle's medium containing 4500 mg/l glucose, 10% fetal bovine serum, 100 U penicillin/ml and 100 mg streptomycin/ml.
HepG2, were cultured in minimal essential medium, 10% heat inactivated fetal calf serum, non-essential amino acids and 1 mM sodium pyruvate.
Human prostate adenocarcinoma cells (LNCaP) were cultured in Rosewell Park Memorial Institute media 1640, 10% fetal bovine serum and 100 U/penicillin and 100 mg streptomycin/ml.
Gene reporter constructs
A 330 bp fragment of the promoter region was amplified (promoter-specific primers Table 5b) using genomic DNA from an individual homozygous for the A allele. The product was subcloned into pcp2.1 vector (Invitrogen, Carlsbad, CA, USA) and then cleaved with KpnI and XhoI and subcloned into KpnI/XhoI sites of pGL2 Basic Luciferase vector (Promega, Madison, WI, USA), resulting in the pGL2AKR1C3A construct.
The polymorphic site was inserted using Stratagene QuickChange Site-Directed Mutagenesis Kit resulting in the pGL2AKR1C3G construct. The PCRs were carried out using 50 ng template DNA (pGL2AKR1C3A), 125 ng of each mutagenic primer 5 0 ccatataagactgcctGtgtacctcctcctacatgcc, and 5 0 ggcatgtaggaggaggtacaCaggcagtcttatatgg, 0.1 mM dNTP mix, 1 Â reaction buffer (Stratagene, La Jolla, CA, USA) and 2.5 U Pfu Turbo DNA polymerase (Stratagene). PCRs started with activation at 951C, 30 s and were then carried out in 13 cycles each involving denaturation at 951C, 30 s, annealing at 551C, 1 min and elongation at 681C, 1 min/kb. PCR products were incubated for 1 h at 371C with 10 U Dpn 1 (Stratagene) whereafter the DNA was transformed into E coli XL-1 Blue. All the sequences were verified by sequence analysis. Plasmids were purified using QIAGEN Endotoxin Free Kit.
Transfection assay
Human lung (A549), liver (HepG2) and prostate (LNCaP) cells were plated in 35 mm 6-well plates at a density of 2 Â 10 5 cells per well and incubated overnight. The cells were transfected using 15 ml lipofectin (Invitrogen), 5 mg of pGL2-basic luciferase plasmid and 1 mg pRL-TK control vector (in LNCaP cells) or beta-galactosidase control vector (in A549 and HepG2 cells). The cells were incubated in serum-free media at 371C for 3-5 h. The transfection solution was then replaced with fresh media containing serum. Cells were harvested 48 h later and luciferase and beta-galactosidase activity were determined according to the manufacturer's description (Promega). Beta-galactosidase values were corrected for endogenous cellular galactosidase activity.
The transfections were performed in duplicates and repeated five times in the A549 and HepG2 cells and three times in the LNCaP cells. The statistical significance was determined by paired t-test.
Expression vector construction AKR1C3 cDNA was amplified from human liver cDNA using the following pairs of oligonucleotides: 5 0 catcatatggattcc aaacagca and 5 0 tctgcatgctaatattcatctg. The amplified DNA was treated with restriction endonucleases Nde I and Sph I before ligation with Nde I-and Sph I-treated expression vector PSP19T7LT4 (an expression plasmid derived from pSPORT-1 (GIBCO, Invitrogen, Carlsbad, CA, USA)) resulting in the 19T7-AKR1C3Glu77 construct. The sequence was verified by sequence analysis. Plasmids were purified using QIAGEN Mini Prep Kit.
The polymorphic site was inserted to generate the 19T7-AKR1C3Gly77 construct. We used Stratagene QuickChange Site-Directed Mutagenesis Kit, as described above, with 50 ng template DNA (AKR1C3Glu77) and 125 ng of each mutagenic primer 5 0 gcagatggcagtgtgaagagagGagacatattcta cacttc and 5 0 gaagtgtagaatatgtctCctctcttcacactgccatctgc. The sequence was verified by sequence analysis. Plasmids were purified using QIAGEN Mini Prep Kit.
Expression of AKR1C3Glu77 and AKR1C3Gly77
The 19T7-AKR1C3Glu77 and the 19T7-AKR1C3Gly77 constructs were transformed into competent E. coli strain DE3(BL21) cells under the control of the lacUV5 promoter. Cells were grown at 371C in 1-l cultures in the presence of 100 mg/ml ampicillin and growth was monitored spectrophotometrically. Non-transformed control cells were grown in cultures of Luria-Bertani media without ampicillin. When the A 600 reached 0.6, protein expression was induced by addition of 1 mM isopropyl-b-D-thiogalactopyranoside and the temperature was lowered to 301C. After 3 h of incubation the cells were pelleted by centrifugation at 2800 Â g for 10 min. The pellets were freeze/thawed once to increase the protein yield. CelLytic (Sigma Aldrich) 10-20 ml per gram cell paste was added to lyse the cells according to the manufacturer's protocol. Protein concentrations in the cytosols were determined by the method of Peterson. 33 The bacterial cytosols containing the recombinant protein were stored in aliquots at À801C.
Western blotting
Proteins were separated on a 12% polyacrylamide gel and electrotransferred onto Hybond-C extra membrane (Amersham, Uppsala, Sweden), blocked overnight in high salt base buffer (50 mM Tris-HCl/500 mM NaCl, pH 7.5), 10% dried milk and incubated for 1 h with 1:6000 diluted mouse antiporcine dihydrodiol dehydrogenase antibody (Exalpha Biologicals Inc). Membranes were washed in HSBT (0.05% Tween þ high salt buffer) and incubated for one hour with 1:1000 horseradish peroxidase-linked anti-mouse immunoglobulin G (Rockland, Minden, USA). The bands were detected by chemiluminescence.
Enzyme incubations
Assays of the polymorphic enzyme activities were carried out in a reaction mixture containing 1-150 mM substrate, 0.5 mg bacterial lysate and 50 mM potassium phosphate buffer, pH 7.4 in a final volume of 500 ml and pre-incubated for 10 min at 371C. The reactions were started by addition of nicotinamide adenine dinucleotide phosphate dehydrogenase (NADPH) or NADP þ at a final concentration of 1 mM. Incubations were continued for 30 min at 371C. At the end of the incubations 1 mg methyltestosterone was added to each sample as an internal standard, pH was raised to 9.6 by addition of 50 ml 20% potassium carbonate solution to increase the extraction yield. The steroids were extracted twice in 5 ml n-pentane by shaking for 10 min. After centrifugation the combined organic phases were evaporated to dryness under a stream of nitrogen. Samples were converted into the enol-trimethylsilyl ether derivatives with N-methyl-N-trimethylsilyltrifluoroacetamide (MacheryNagel, Düren, Germany) and ammonium iodide as described previously. 34 Metabolites of the enzyme reactions were determined using the combined gas chromatography-mass spectrometry GC/MS technique. The analysis was performed with an Agilent GC-MS 5973 instrument using the Single Ion Monitoring mode.
Analytes were identified, peaks were integrated and calculated using one point calibration with the mixture of authentic standard materials analyzed with every batch of samples. The limit of detection (LOD) was determined as o 10 ng/ml for androstenedione (4-dione), DHT and androsterone, o6.0 ng/ml for 3a-Adiol, 3b-Adiol and o 2.5 ng/ml for testosterone and epiandrosterone. The recovery of the steroids was 490% and the day-to-day variation of the instrument could be corrected for using the mixture of authentic standard materials analyzed with every batch of samples.
Abbreviations
AKR aldoketoreductase 3a-HSD 3a-hydroxysteroid dehydrogenase 17b-HSD 17b-hydroxysteroid dehydrogenase PGFS prostaglandin F synthase SSCP single-strand conformation polymorphism 3a-diol 5a-androstane-3a,17b-diol EpiT epitestosterone 5a-DHT 5a-dihydrotestosterone USF upstream stimulating factor
